DOSE OF REALITY: BIG PHARMA’S EGREGIOUS GLP-1, GENE, AND CELL THERAPY PRICES PROJECTED TO INCREASE HEALTH CARE COSTS FOR EMPLOYERS
Analysis Finds GLP-1 Blockbusters and “Multimillion-Dollar Gene Therapies”… Read More
Analysis Finds GLP-1 Blockbusters and “Multimillion-Dollar Gene Therapies”… Read More
Avik Roy Highlights How Increased USPTO-FDA Collaboration and Greater Scrutiny… Read More
Research Article Explores Negative Implications of Proposal to Restrict Key… Read More
Research Column Explores Case Study in Common Patent Abuse Tactic That… Read More
Senate Hearing Offers Opportunity to Highlight Market-Based Solutions to Hold… Read More
Analysis Showcases Egregious Scale of Big Pharma’s Patent Thickets on… Read More
Analysis Shows Price Hikes Outpacing Inflation, Rising Launch Prices and… Read More
Reports Find Biosimilars Have Lower Prices Than Brand Name Biologics… Read More
Two Reports Explore Cost for U.S. Patients and the U.S. Health Care System of… Read More
CBO Says Cost to Taxpayers of Covering GLP-1 Medications Would Outpace Savings… Read More
Patent Abuse Designed to Extend Monopolies, Block Competition and Keep Prices… Read More
JAMA Analysis Finds Patents for Active Ingredients for Weight Loss Drugs… Read More